{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:03:15Z","timestamp":1791892995817,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaip.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:23:31Z","timestamp":1790292211000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Immune Checkpoint Inhibitors Targeting Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 and Type 2 Airway Inflammation in Patients With Lung Cancer: The IMMUNEO Retrospective Case Series"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0517-2521","authenticated-orcid":false,"given":"Zakaria","family":"Lahmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-8042","authenticated-orcid":false,"given":"Joana","family":"Pissarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl-Morvan","family":"Duroyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreanne","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Charriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.09.008_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2026.09.008_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaip.2026.09.008_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jtho.2019.02.031","article-title":"Immune-related adverse events and outcomes in patients with advanced non\u2013small cell lung cancer: a predictive marker of efficacy?","volume":"14","author":"Remon","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaip.2026.09.008_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.638","article-title":"Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab","volume":"8","author":"Watanabe","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.09.008_bib6","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1084\/jem.20170051","article-title":"ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control","volume":"214","author":"Schwartz","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/biomedicines12081886","article-title":"Review of T helper 2-type inflammatory diseases following immune checkpoint inhibitor treatment","volume":"12","author":"Mima","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2026.09.008_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2026.09.008_bib9","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/annonc\/mdx455","article-title":"Nivolumab-induced asthma in a patient with non-small-cell lung cancer","volume":"28","author":"Maeno","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2026.09.008_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1165\/rcmb.2009-0258OC","article-title":"Programmed death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma","volume":"43","author":"McGee","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2026.09.008_bib11","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1084\/jem.20161653","article-title":"PD-1 regulates KLRG1+ group 2 innate lymphoid cells","volume":"214","author":"Taylor","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31757-z","article-title":"PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses","volume":"8","author":"Rosskopf","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2026.09.008_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaip.2020.08.022","article-title":"PD-L1 inhibitor-induced worsening of eosinophilic obstructive lung disease successfully rescued with anti-interleukin 5 receptor (IL-5R) therapy","volume":"9","author":"Wassmer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.008_bib14","article-title":"Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: a case report","volume":"49","author":"Harada","year":"2024","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.09.008_bib15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1183\/09031936.00144208","article-title":"COPD prevalence is increased in lung cancer, independent of age, sex and smoking history","volume":"34","author":"Young","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.09.008_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P930","article-title":"Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort","volume":"44","author":"Vogelmeier","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.09.008_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib18","first-page":"152","article-title":"Association between peripheral eosinophils and clinical outcomes in patients with non\u2013small cell lung cancer treated with immune checkpoint inhibitors","volume":"131","author":"Okauchi","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib19","article-title":"Time-to-treatment failure and peripheral eosinophils in non\u2013small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"131","author":"Osawa","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1164\/rccm.201704-0795OC","article-title":"Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non\u2013small cell lung cancer","volume":"197","author":"Mark","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.201706-1110OC","article-title":"Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade","volume":"198","author":"Biton","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/ijc.32235","article-title":"Improved treatment outcome of pembrolizumab in patients with non\u2013small cell lung cancer and chronic obstructive pulmonary disease","volume":"145","author":"Shin","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaip.2026.09.008_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.2007.00869.x","article-title":"Th2-mediated anti-tumour immunity: friend or foe?","volume":"70","author":"Ellyard","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jaip.2026.09.008_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaip.2026.09.008_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.09.008_bib26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2026.09.008_bib27","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2026.09.008_bib28","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.008_bib29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.008_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","article-title":"Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies","volume":"81","author":"Bernard-Tessier","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2026.09.008_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1722022","article-title":"Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jaip.2026.09.008_bib32","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1136\/annrheumdis-2018-213857","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors","volume":"78","author":"Roger","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.008_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227814","article-title":"Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition","volume":"12","author":"Donato","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2026.09.008_bib34","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.3747\/co.26.4859","article-title":"Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer","volume":"26","author":"Blanchard","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaip.2026.09.008_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/iid3.238","article-title":"A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient","volume":"7","author":"Jodai","year":"2019","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaip.2026.09.008_bib36","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/COPD.S214610","article-title":"Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non\u2013small cell lung cancer patients with and without COPD","volume":"14","author":"Suzuki","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jaip.2026.09.008_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaci.2021.06.023","article-title":"Extrafollicular PD-1(high)CXCR5(-)CD4(+) T cells participate in local immunoglobulin production in nasal polyps","volume":"149","author":"Wang","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.008_bib38","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41467-020-17813-1","article-title":"PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity","volume":"11","author":"Helou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2026.09.008_bib39","article-title":"Independent factors associate with hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease requiring intensive care unit admission: Focusing on the eosinophil-to-neutrophil ratio","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982600783X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982600783X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:32:28Z","timestamp":1791891148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982600783X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S221321982600783X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.008","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Immune Checkpoint Inhibitors Targeting Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 and Type 2 Airway Inflammation in Patients With Lung Cancer: The IMMUNEO Retrospective Case Series","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}